Mazor Robotics Ltd. (MZOR) Given a $67.00 Price Target at Ladenburg Thalmann Financial Services

Ladenburg Thalmann Financial Services set a $67.00 target price on Mazor Robotics Ltd. (NASDAQ:MZOR) in a report published on Monday morning. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

MZOR has been the topic of a number of other reports. Needham & Company LLC reissued a hold rating on shares of Mazor Robotics in a report on Thursday, July 6th. Barclays PLC downgraded Mazor Robotics from an equal weight rating to an underweight rating and reduced their price objective for the stock from $55.00 to $34.00 in a research note on Thursday, October 19th. Finally, Zacks Investment Research downgraded Mazor Robotics from a strong-buy rating to a hold rating in a research note on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $39.83.

Shares of Mazor Robotics (MZOR) traded up 7.11% during midday trading on Monday, hitting $64.32. 1,028,778 shares of the stock were exchanged. Mazor Robotics has a 52-week low of $20.19 and a 52-week high of $65.97. The stock’s market cap is $1.55 billion. The firm’s 50 day moving average price is $51.05 and its 200-day moving average price is $41.65.

Mazor Robotics (NASDAQ:MZOR) last posted its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The firm had revenue of $15.46 million for the quarter, compared to analysts’ expectations of $15.38 million. During the same period in the previous year, the firm earned ($0.09) EPS. The business’s quarterly revenue was up 86.7% on a year-over-year basis. On average, equities research analysts expect that Mazor Robotics will post ($0.77) earnings per share for the current fiscal year.

WARNING: “Mazor Robotics Ltd. (MZOR) Given a $67.00 Price Target at Ladenburg Thalmann Financial Services” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/10/31/mazor-robotics-ltd-mzor-given-a-67-00-price-target-at-ladenburg-thalmann-financial-services.html.

Several hedge funds have recently modified their holdings of MZOR. Quantbot Technologies LP purchased a new stake in shares of Mazor Robotics in the 2nd quarter worth $135,000. JPMorgan Chase & Co. lifted its holdings in shares of Mazor Robotics by 398.5% in the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock worth $208,000 after buying an additional 5,579 shares during the period. BB&T Securities LLC purchased a new stake in shares of Mazor Robotics in the 2nd quarter worth $248,000. Dimensional Fund Advisors LP lifted its holdings in shares of Mazor Robotics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after buying an additional 641 shares during the period. Finally, ProVise Management Group LLC purchased a new stake in shares of Mazor Robotics in the 2nd quarter worth $422,000. Institutional investors and hedge funds own 25.69% of the company’s stock.

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

What are top analysts saying about Mazor Robotics Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mazor Robotics Ltd. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit